Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

News feed

Board of Directors of EvroTrans recommended dividends

9/1/25 EUTR

SPB Exchange summed up the trading results in August

9/1/25 SPBE

Moscow Exchange to launch credit default swaps

9/1/25 MOEX

Ozon will launch a Fashion Lux section for selling luxury brands

9/1/25 OZON

Azbuka Vkusa cost Magnit 29.6 billion rubles

8/30/25 MGNT

Rosneft's production decreased by 7.4% in the first half of the year

8/30/25 ROSN

Rosneft reports for 6 months of 2025 under IFRS

8/30/25 ROSN

OMZ reported for 6 months of 2025 in accordance with IFRS

8/29/25 OMZZP

Lenenergo reported for 6 months of 2025 under IFRS

8/29/25 LSNG

MCB reported for 6 months of 2025 in accordance with IFRS

8/29/25 CBOM